A Phase 4 interventional study of Sertraline and Bupropion in Major Depressive Disorder, sponsored by Mclean Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Mclean Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing sertraline in Depressive Disorder, Major — 6 open to participants now, 7 under way, none of them phase 3. Sertraline · Depressive Disorder, Major.
Among the 44 studies testing sertraline in Depressive Disorder, Major, this one is the 26th largest by enrollment, is one of 2 that started in 2022, is one of 16 in phase 4, and was the 36th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →6 of the 44 studies testing sertraline in Depressive Disorder, Major are open now, in 4 countries. Recruiting first, the newest first:
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
University of Bern · Sites in Zimbabwe
Ages 18+
Poznan University of Medical Sciences · Sites in Poland
Ages 12+
University of Texas at Austin · Sites in United States
Ages 18–65
By country, each count listing its studies:
Sertraline: first FDA approval 1991 (ZOLOFT). What it is approved for, and how studies give it, is on its page →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 7 · Phase 4 16
First in 1998; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 78 across the 44 interventional studies. Of the 31 that completed or were terminated, 12 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 44 have an industry lead sponsor. The 10 most frequent:
Mclean Hospital is the lead sponsor of 185 studies on the registry; 31 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.
32 studies in Depressive Disorder, Major by Mclean Hospital: 7 open now, 7 under way, none of them phase 3. Of 24 finished, 12 (50%) have results posted.
Among the 32 studies in Depressive Disorder, Major by Mclean Hospital, this one is the 15th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2022, is one of 5 in phase 4, and was the 27th registered.
Mclean Hospital’s Depressive Disorder, Major studies by the year they started, since 2004.
4 of the studies testing sertraline in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05273996David SteffensPredictors of Cognitive Outcomes in Geriatric Depression | 2027-04-30 |
| NCT07011693Xinyu ZhouSwitching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression(SMART-I) | 2027-06 |
| NCT05892744University of Texas at AustinEstablishing Multimodal Brain Biomarkers for Treatment Selection in Depression | 2027-07-15 |
| NCT07478796Poznan University of Medical SciencesTDM-Guided Treatment With SSRIs in Hospitalized Adults and Children | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 44 studies testing sertraline in Depressive Disorder, Major, from their registry updates:
Among Mclean Hospital’s 32 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The main goal of this research is to use behavioral, brain, and clinical data to determine which type of antidepressant might be optimal before people with depression start treatment.
The treatment of depression is often trial-and-error. Earlier research reported that only 50% of individuals with depression show a significant decline in symptoms after taking an antidepressant. The situation is even worse in primary care, where only 30% respond to first line antidepressants.
The difficulty in treating depression is likely because treatment selection is not based on each person's characteristics. While some depressed individuals may benefit from selective serotonin reuptake inhibitors (SSRIs), others might benefit more from other types of medication. Finding markers that predict an individual's response to different antidepressants would provide patients and clinicians with valuable information to guide treatment selection.
The present study is among the first to use clinical (e.g., responses on questionnaires), behavioral (e.g., performance in computerized tasks), and brain (e.g., MRI scans) data to guide treatment selection in order to increase the likelihood of benefiting from one of two antidepressants. After analyzing an individuals' markers, subjects will be randomly assigned to receive a full 8-week course of an SSRI or non-SSRI.
Throughout the study, participants will complete 9 total sessions over the course of 9-10 weeks, including an electroencephalogram (EEG) recording, a functional magnetic resonance imaging (fMRI) scan, an electrocardiogram (EKG) exam, interviews with clinicians, and a full 8-week course of an antidepressant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Lifetime history of other recreational drug use beyond the following limits (for each drug individually) and/or last use within the past 3 months:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with MDD who have been classified as high sertraline responders based on behavioral and brain data.
Drug: Sertraline · Drug: Bupropion
Participants with MDD who have been classified as high bupropion responders based on behavioral and brain data.
Drug: Sertraline · Drug: Bupropion
Subjects will receive 8 weeks of sertraline while monitored by the study physician
Also known as: Zoloft
Subjects will receive 8 weeks of bupropion while monitored by the study physician
Also known as: Wellbutrin
Montgomery-Åsberg Depression Rating Scale (MADRS)
The Montgomery-Åsberg Depression Rating Scale (MADRS) - Clinician-Rated Scale measures depressive symptom severity and is administered by a trained clinician. The scale includes 10 items assessing symptoms such as sadness, inner tension, sleep, appetite, concentration, energy, anhedonia, pessimistic thoughts, and suicidal thoughts. Each item is rated from 0-6, with a total score range of 0-60, calculated by summing all item scores. Higher scores indicate greater depression severity (worse outcome), whereas lower scores indicate fewer depressive symptoms (better outcome).
Time frame: Baseline and Week 8 of treatment/outcome assessment session
Ventral-striatal Activation During Reward Related Tasks in an fMRI Scan
Brain measure of anhedonia
Time frame: 8-10 weeks
Effort-based Decision Making During an Effort-based Task
Behavioral measure of anhedonia
Time frame: 8-10 weeks
Reward Positivity During a Guessing Monetary Reward Task
Behavioral measure of anhedonia
Time frame: 8-10 weeks
Cortico-insular Activation During an Effort-based Task
Brain measure of anhedonia
Time frame: 8-10 weeks
Resting State Functional Connectivity Between the NAc and mPFC During an fMRI Scan
Brain measure of anhedonia
Time frame: 8-10 weeks
Participants were enrolled at McLean Hospital between September 30, 2022, and August 26, 2025. Eligible adults (18-64) met DSM-5-TR MDD criteria via SCID-5, with HRSD\>15 and SHAPS\>24, limited treatment resistance, and no major comorbidities or contraindications to the medications. All were medication-free, provided written informed consent, and were compensated.
| Milestone | Bupropion +/Sertraline + and BUP Treatment | Bupropion +/Sertraline + and SER Treatment | Bupropion +/Sertraline - and BUP Treatment | Bupropion +/Sertraline - and SER Treament | Bupropion -/Sertraline + and SER Treatment | Bupropion -/Sertraline + and BUP Treatment | Bupropion - /Sertraline - and BUP Treatment | Bupropion -/Sertraline - and SER Treatment |
|---|---|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 10 | 5 | 5 | 2 | 5 |
| Completed | 6 | 5 | 5 | 8 | 3 | 5 | 2 | 4 |
| Not completed | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 1 |
The Montgomery-Åsberg Depression Rating Scale (MADRS) - Clinician-Rated Scale measures depressive symptom severity and is administered by a trained clinician. The scale includes 10 items assessing symptoms such as sadness, inner tension, sleep, appetite, concentration, energy, anhedonia, pessimistic thoughts, and suicidal thoughts. Each item is rated from 0-6, with a total score range of 0-60, calculated by summing all item scores. Higher scores indicate greater depression severity (worse outcome), whereas lower scores indicate fewer depressive symptoms (better outcome).
| Score on a scale | Bupropion +/Sertraline + and BUP Treatment | Bupropion +/Sertraline + and SER Treatment | Bupropion +/Sertraline - and BUP Treatment | Bupropion +/Sertraline - and SER Treatment | Bupropion -/Sertraline + and SER Treatment | Bupropion -/Sertraline + and BUP Treatment | Bupropion - /Sertraline - and BUP Treatment | Bupropion -/Sertraline - and SER Treatment |
|---|---|---|---|---|---|---|---|---|
| Montgomery-Åsberg Depression Rating Scale (MADRS) | -20.33 ± 7.03 | -15.80 ± 15.55 | -11.60 ± 11.55 | -22.50 ± 8.14 | -22.00 ± 8.89 | -15.67 ± 6.66 | -12.00 ± 5.66 | -8.25 ± 11.03 |
Brain measure of anhedonia
Results for this outcome have not been posted.
Behavioral measure of anhedonia
Results for this outcome have not been posted.
Behavioral measure of anhedonia
Results for this outcome have not been posted.
Brain measure of anhedonia
Results for this outcome have not been posted.
Brain measure of anhedonia
Results for this outcome have not been posted.
Collected over from enrollment until end of study procedures, up to 10 weeks of participation, including 8-week treatment period. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bupropion +/Sertraline + and BUP Treatment | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Bupropion +/Sertraline + and SER Treatment | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| Bupropion +/Sertraline - and BUP Treatment | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Bupropion +/Sertraline - and SER Treatment | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Bupropion -/Sertraline + and SER Treatment | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Bupropion -/Sertraline + and BUP Treatment | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Bupropion - /Sertraline - and BUP Treatment | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Bupropion -/Sertraline - and SER Treatment | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| No Marker Assigned and no Medication | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Bupropion +/Sertraline + and BUP Treatment | Bupropion +/Sertraline + and SER Treatment | Bupropion +/Sertraline - and BUP Treatment | Bupropion +/Sertraline - and SER Treatment | Bupropion -/Sertraline + and SER Treatment | Bupropion -/Sertraline + and BUP Treatment | Bupropion - /Sertraline - and BUP Treatment | Bupropion -/Sertraline - and SER Treatment | No Marker Assigned and no Medication |
|---|---|---|---|---|---|---|---|---|---|
| Claustrophobic symptomsGeneral disorders | 0/7 | 0/7 | 1/7 | 0/10 | 0/5 | 0/5 | 0/2 | 0/5 | 1/1 |
| Vasovagal response to blood drawGeneral disorders | 1/7 | 0/7 | 0/7 | 0/10 | 0/5 | 0/5 | 1/2 | 0/5 | 0/1 |
| AppendicitisGastrointestinal disorders | 0/7 | 0/7 | 0/7 | 0/10 | 0/5 | 1/5 | 0/2 | 0/5 | 0/1 |
| Side effect to medication: NauseaGeneral disorders | 0/7 | 0/7 | 0/7 | 2/10 | 0/5 | 0/5 | 0/2 | 0/5 | 0/1 |
| Side-effects to medication: InsomniaGeneral disorders | 0/7 | 0/7 | 1/7 | 2/10 | 0/5 | 0/5 | 0/2 | 1/5 | 0/1 |
| Side-effects to medication: Decreased appetiteGeneral disorders | 0/7 | 0/7 | 1/7 | 1/10 | 0/5 | 0/5 | 0/2 | 1/5 | 0/1 |
| Side-effects to medication: HeadacheGeneral disorders | 0/7 | 0/7 | 0/7 | 1/10 | 0/5 | 0/5 | 0/2 | 1/5 | 0/1 |
| Side-effects to medication: Worsen in depressive symptomsGeneral disorders | 0/7 | 0/7 | 1/7 | 0/10 | 0/5 | 0/5 | 0/2 | 0/5 | 0/1 |
All randomized participants were included in the baseline characteristics analysis. All participants completed at least 1 week of treatment and had sufficient information to determine baseline biomarker status. Baseline characteristics are reported according to the randomized study arms, which correspond to biomarker status and randomized treatment assignment.
| Age, Continuous(Years) | Bupropion +/Sertraline + and BUP Treatment | Bupropion +/Sertraline + and SER Treatment | Bupropion +/Sertraline - and BUP Treatment | Bupropion +/Sertraline - and SER Treatment | Bupropion -/Sertraline + and SER Treatment | Bupropion -/Sertraline + and BUP Treatment | Bupropion - /Sertraline - and BUP Treatment | Bupropion -/Sertraline - and SER Treatment | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 28.14 ± 2.85 | 35.29 ± 12.94 | 25.86 ± 5.55 | 30.60 ± 7.66 | 27.00 ± 5.10 | 33.40 ± 8.91 | 20.50 ± 3.54 | 23.40 ± 2.97 | 29.0 ± 8.1 |
| Sex: Female, Male(Participants) | Bupropion +/Sertraline + and BUP Treatment | Bupropion +/Sertraline + and SER Treatment | Bupropion +/Sertraline - and BUP Treatment | Bupropion +/Sertraline - and SER Treatment | Bupropion -/Sertraline + and SER Treatment | Bupropion -/Sertraline + and BUP Treatment | Bupropion - /Sertraline - and BUP Treatment | Bupropion -/Sertraline - and SER Treatment | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 6 | 7 | 7 | 3 | 2 | 2 | 3 | 35 |
| Male | 2 | 1 | 0 | 3 | 2 | 3 | 0 | 2 | 13 |
| Race (NIH/OMB)(Participants) | Bupropion +/Sertraline + and BUP Treatment | Bupropion +/Sertraline + and SER Treatment | Bupropion +/Sertraline - and BUP Treatment | Bupropion +/Sertraline - and SER Treatment | Bupropion -/Sertraline + and SER Treatment | Bupropion -/Sertraline + and BUP Treatment | Bupropion - /Sertraline - and BUP Treatment | Bupropion -/Sertraline - and SER Treatment | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 4 | 2 | 1 | 0 | 1 | 1 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 4 |
| White | 6 | 3 | 3 | 4 | 1 | 4 | 1 | 3 | 25 |
| More than one race | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 2 | 0 | 1 | 1 | 1 | 0 | 1 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We are part of a large team of researchers across the US called MCPsych which is funded through the Wellcome Leap Grant. We have a large repository of questionnaires, behavioral, and brain data that will be collected similar across sites and allow additional data analyses.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Within 12 months after data collection is completed
Access criteria: Access will be governed by the Multi-Channel Psych department of the Wellcome Leap foundation.
Ran from Sep 2022 to primary completion in Aug 2025, 34 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 79 non-industry phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 34 months is below that.
Counting every sponsor, half of 98 studies reached it within 35 months; a quarter within 20 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sertraline · Bupropion